We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement

Mouse DNA to aid Biomedical Research


Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Mouse DNA to aid Biomedical Research"

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Read time:
 

Researchers have announced that they have resequenced the DNA of 15 mouse strains most commonly used in biomedical research. 

8.3 million SNPs were discovered among the genomes of the 15 mouse strains and the data are now publicly available. 

These data will help researchers better understand complex genetic traits, such as why some individuals are more susceptible to certain diseases, and will serve as a valuable resource in determining how environmental agents influence the development of disease.

"Making this wealth of data freely available to the research community is a significant milestone," said David A. Schwartz. M.D., director of the National Institute of Environmental Health Sciences (NIEHS), part of the National Institutes of Health, which funded the research. 

"Each mouse strain is genetically unique. Now that we know the DNA variations
for these mouse strains, we can compare the genetic makeup of one strain
that acquires a certain disease to another strain that does not get the same disease." 

"In this way researchers gain insight into the same processes that may cause one human to get a disease while another human in the same environment remains disease-free."

The "Resequencing and SNP Discovery Project" began less than two years ago through a contract between the National Toxicology Program at NIEHS and Perlegen Sciences, Inc. of Mountain View CA. 

Perlegen scientists conducted the project using as a standard reference the 2003 DNA sequencing of the C57BL/6J mouse strain - the very first mouse strain to undergo DNA sequencing. 

The mouse models included in the resequencing project are: 129S1/SvImJ, A/J, AKR/J, BALB/cByJ, BTBR T+ tf/J, C3H/HeJ, CAST/EiJ, DBA/2J, FVB/NJ, MOLF/EiJ, KK/HlJ, NOD/LtJ, NZW/LacJ, PWD/PhJ, and WSB/EiJ.

The 15 mouse strains were carefully chosen because of their routine use as research models and their genetic diversity. 

The project used the same high-density oligonucleotide array technology that was used to discover common DNA variation in the human genome.

"Perlegen Sciences was excited to perform this scientific work, because it promised to provide an extremely valuable resource. We believe the data will generate a lot of knowledge about complex genetic traits," said Kelly Frazer, Vice President of Genomics at Perlegen Sciences, Inc.

"This project was highly anticipated by scientists. Now, we can go to our  computer, click on the mouse strain we want to use, see the sequence variations for that strain and compare it to the others," said David Threadgill, Ph.D., University of North Carolina, Chapel Hill.

"If we use multiple strains, we can then look at the data after the animals are exposed to an environmental substance and compare the genetic differences between the strains that acquired a disease and those that did not."

"This will help us begin to identify causes of differential susceptibility to disease."

"These mouse data will aid in our understanding of 'counterpart' genes in humans, the corresponding molecular and biological pathways the lead to disease susceptibility, and the environmental agents that trigger the development of disease in susceptible people," said David Christiani, M.D., Professor of Medicine at Harvard Medical School and Professor of Occupational Medicine and Epidemiology at Harvard School of Public Health.

"The data will also be a great resource for pharmaceutical companies that are developing new treatments for disease."

Advertisement